	US 11,732,306 B2
	Molecular subtyping of small cell lung cancer to predict therapeutic responses
Carl M. Gay, Houston, TX (US); Lauren A. Byers, Houston, TX (US); and John V. Heymach, Houston, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Sep. 3, 2020, as Appl. No. 17/11,519.
Claims priority of provisional application 62/895,322, filed on Sep. 3, 2019.
Prior Publication US 2021/0062274 A1, Mar. 4, 2021
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/154 (2013.01)]

14 Claims

1. A method of treating a human patient having an inflamed-subtype of small cell lung cancer (SCLC-I), the method comprising administering a therapeutically effective amount of an immune checkpoint inhibitor or a Bruton's tyrosine kinase (BTK) inhibitor to the patient, wherein the patient's cancer has been determined to be ASCL1, NEUROD1, and POU2F3 triple negative.